

Weight Loss Medications

Drug	Mechanism/ Dosage Form	Dosing	% TBWL	Side Effects	Warnings & Precautions	Monitoring/Notes
Orlistat Brands: Xenical, Alli	Lipase Inhibitor: inhibits absorption of dietary fats by 30% <i>Oral Capsule</i>	Xenical: 120 mg TID with meals Alli (OTC): 60 mg TID with meals *Use with a low fat diet *Omit dose if meal is missed or contains no fat	1 yr: 4% 4 yr: 2.6%	Frequent GI side effects including: steatorrhea, fecal urgency, flatulence, incontinence, oily spotting, frequent BM *Eating >30% kcal from fat results in greater GI side effects <ul style="list-style-type: none"> Headache Abdominal pain Back pain Respiratory tract infection 	Contraindicated in: <ul style="list-style-type: none"> Pregnancy/breast-feeding Malabsorption syndrome Cholestasis May Cause: <ul style="list-style-type: none"> Oxalate kidney stones Hepatotoxicity Malabsorption of fat soluble vitamins 	<ul style="list-style-type: none"> Cholelithiasis Nephrolithiasis Renal function *Separate by 4h from levothyroxine *Take MVI with fat-soluble vitamins > 2h before or after FDA approved age 12 and older
Phentermine	NE - Releasing Agent: properties similar to stimulants, reduces appetite <i>Oral Capsule</i> <i>Oral Tablet</i>	Capsule: 15 – 37.5 mg daily given in one or two divided doses *Short-term (few weeks) use only	3.0 – 10.7 % short term (3 mth) to longer term (24 mth) use	<ul style="list-style-type: none"> Elevated BP, HR Dizziness Dysphoria/euphoria Insomnia Diarrhea Constipation Change in libido Dry mouth 	Contraindicated in: <ul style="list-style-type: none"> Pregnancy/breast-feeding CVD (arrhythmia, CHF, CAD, stroke) Uncontrolled HTN Hyperthyroidism Hx of drug abuse Use within 14 days of MAOI Glaucoma Caution with: <ul style="list-style-type: none"> CNS depression Cardiac toxicity Seizure disorder 	<ul style="list-style-type: none"> Blood Pressure Heart Rate Psychosis Dependency/Withdrawal FDA approved age 16 and older
Phentermine/ Topiramate ER Brand: Qsymia	NE - Releasing Agent: Phentermine: see above, reduces appetite GABA Receptor Modulator: Topiramate: increases satiety and appetite suppression <i>Oral Capsule</i>	Starting Dose: 3.75/23 mg PO daily x 2 weeks Recommended Dose: 7.5/46 mg PO daily x 12 weeks and evaluate Escalation Dose: 11.25/69 mg PO daily x 2 weeks Max Dose: 15/92 mg PO daily x 12 weeks and evaluate *Requires dose adjustments with hepatic and renal impairment	1 yr: ~ 9% on high dose, 6.6% on treatment dose 2 yr: 8.7% high dose, 7.5% treatment dose *Evaluate response at max dose, if 5% BW not lost then D/C	<ul style="list-style-type: none"> Increased BP, HR Headache Paresthesia Insomnia Decreased bicarbonate Dry mouth Constipation Nasopharyngitis Anxiety/depression Concentration/memory impairment Dizziness 	Contraindicated in: <ul style="list-style-type: none"> Pregnancy/breast-feeding Hyperthyroidism Use within 14 days of MAOI Glaucoma May Cause: <ul style="list-style-type: none"> Anxiety/panic attacks Seizure Disorder Caution with bipolar Nephrolithiasis Hyperchloremic metabolic acidosis Cognitive impairment 	<ul style="list-style-type: none"> Increased HR S/Sx of depression Dependency Withdrawal Hypokalemia Acute myopia or eye pain Kidney stones Monthly pregnancy tests Menstrual spotting with OCPs Hypoglycemia in pts with T2DM FDA approved age 12 and older

Weight Loss Medications

Drug	Mechanism/ Dosage Form	Dosing	% TBWL	Side Effects	Warnings & Precautions	Monitoring/Notes
Naltrexone/ Bupropion Brand: Contrave	Opioid Antagonist: naltrexone NE/DA Reuptake Inhibitor: bupropion <i>Oral Tablet</i>	Initial: 1 tablet (8 mg/90 mg) daily QAM x 1 week Titrate Dose: Week 2: 1 tab BID Week 3: 2 tabs QAM and 1 tab QPM Week 4: 2 tabs BID *Requires dose adjustments with hepatic and renal impairment	1 yr: 4.2-5.2% *Evaluate response at maximum dose at 12 weeks. If pt has not lost at least 5% of BW then D/C	<ul style="list-style-type: none"> • Nausea/Vomiting • Diarrhea • Constipation • Headache • Insomnia • Dizziness • Dry mouth • Anxiety 	Contraindicated in: <ul style="list-style-type: none"> • Pregnancy/breast-feeding • Uncontrolled HTN • Chronic opioid use • Seizure disorder • Anorexia/Bulimia nervosa • Use within 14 days of MAOI • Severe Depression Caution with: <ul style="list-style-type: none"> • GAD, bipolar disorder, suicidal ideation • Arrhythmia • Glaucoma 	<ul style="list-style-type: none"> • HR, BP • Worsening depression • Worsening headache • Seizures (bupropion lowers seizure threshold) *Can cause false (+) urine amphetamine *CYP2D6 drug interactions – clopidogrel FDA approved age 18 and older
Liraglutide Brand: Saxenda Victoza	GLP-1 Receptor Agonist: slows gastric emptying, decreases food intake <i>Subcutaneous Injection</i>	Initial: 0.6 mg SC once daily x 1 week Titrate Dose: Increase by 0.6 mg every week until max dose of 3 mg SC daily	1 yr: 5.6% *Evaluate response after 16 weeks, if pt has not lost at least 4% of BW then D/C	<ul style="list-style-type: none"> • Nausea/Vomiting • Diarrhea • Constipation • Headache • Increased HR • Dyspepsia 	Contraindicated in: <ul style="list-style-type: none"> • Pregnancy/breast-feeding • Personal or FHx of medullary thyroid cancer or MEN2 May Cause: <ul style="list-style-type: none"> • Pancreatitis • Gallbladder disease Caution with: <ul style="list-style-type: none"> • Gastroparesis 	<ul style="list-style-type: none"> • Pancreatitis • Cholelithiasis • Hypoglycemia with insulins or SFUs • Dehydration from N/V • Injection site reactions FDA approved age 12 and older
Semaglutide Brands: Ozempic Rybelsus Wegovy	GLP-1 Receptor Agonist: slows gastric emptying, decreases food intake <i>Subcutaneous Injection</i> <i>Oral tablet (Rybelsus)</i>	Initial: 0.25 mg SC weekly x 4 weeks Titrate Dose: Ozempic: 0.5 mg weekly x 4 doses then increase every 4 weeks to 1.0, 2.0 mg per week Rybelsus: no changes to current copy Wegovy: 0.5 mg weekly x 4 doses then increase every 4 weeks to 1.0, 1.7, 2.4 mg per week	SC: 68 weeks: 10 – 16 % Oral: 26 weeks: mean 3.8 kg weight loss	See above for Liraglutide	FDA approved age 12 and older	